Down 57% in 3 months while the S&P 500 fell 5%.
−3Long-term trend
UPB's Quality Score rose 2 points on Fri, Nov 6, to -9. Buying reached its highest in 20 days (2 chart checks started).
Follow UPB's trial news. Pro members can get an alert when Upstream Bio files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 10.7% a day with no profit behind it |
| Latest filing | 10-Q, Aug 11 |
ReportExpected to report tomorrow, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -0.2% on average. Past reports ›
After its last 4 reports it closed -0.3% on average, higher 2 of 4 times.
About 7 quarters
Chief Medical Officer Aaron Deykin sold 895 shares on Sep 16. 14 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
UPB is #273 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 273 |
Expected to report Tue Nov 10, before the open (tomorrow).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease of $1.8 million was primarily driven by a decrease in manufacturing expenses, partially offset by an increase in personnel-related expenses, including share-based compensation, and an increase in clinical costs related to the Company’s verekitug programs.”
UPB's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease of $0.3 million was primarily driven by a decrease in professional fees, partially offset by an increase in personnel-related expenses, including share-based compensation.”
From its results filing (SEC filing · Aug 11)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 11, 2026 | +0.5% | -4.7% | -4.0% |
| May 13, 2026 | +0.1% | +4.6% | -10.3% |
| Mar 26, 2026 | +0.1% | +3.4% | -1.7% |
Sales grew in one of the last two years, to $2.9M in 2025. It lost money in each of the three years.
RSI 40.1, MACD above signal, below both averages. Not scored.
5 insiders sold $58K across 10 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: UPB is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
“The biopharmaceutical industry is characterized by rapid advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates.”
UPB scores -9 today, which Breakaway calls Poor. It is #273 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 57% in 3 months while the S&P 500 fell 5%. Cash lasts about 7 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
UPB scores -9 today, which Breakaway calls Poor (below zero). That is #273 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind UPB's -9.
5 insiders sold $58K across 10 filings in the last 6 months. No open-market buys on record. The newest is Everett Rand Sutherland, Chief Executive Officer, who sold $12K on Sep 16. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.